Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oba01 in DR5 Positive NSCLC
NCT06083870Phase 1Recruiting
- Start
- Dec 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Oba01 in non-small cell lung cancer (NSCLC). Primary endpoint: Maximal Tolerance Dose at 21 days. Started Dec 2023; status: recruiting.
02
Drugs
Oba01
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06083870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083870.